The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria. Iptacopan (Fabhalta, Novartis) is an oral selective complement factor B inhibitor designed to be given as ...
InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback